Insmed (INSM) Scheduled to Post Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Insmed to post earnings of ($1.21) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The firm had revenue of $83.70 million during the quarter, compared to analyst estimates of $82.15 million. The firm’s quarterly revenue was up 41.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.20) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Insmed Stock Up 1.6 %

Shares of Insmed stock opened at $25.95 on Tuesday. Insmed has a 12-month low of $18.08 and a 12-month high of $32.00. The stock’s fifty day moving average is $26.72 and its 200-day moving average is $27.07.

Analyst Upgrades and Downgrades

A number of research firms have commented on INSM. Barclays upped their price objective on shares of Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Wolfe Research started coverage on shares of Insmed in a research note on Thursday, February 15th. They issued an “outperform” rating and a $42.00 price objective for the company. UBS Group began coverage on shares of Insmed in a research report on Tuesday, February 27th. They set a “buy” rating and a $46.00 price objective on the stock. Wells Fargo & Company restated an “overweight” rating and issued a $55.00 target price on shares of Insmed in a report on Monday, April 1st. Finally, Guggenheim raised their target price on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.92.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.